| 2.87 0.03 (1.06%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.51  |
1-year : | 4.1 |
| Resists | First : | 3 |
Second : | 3.51 |
| Pivot price | 2.24 |
|||
| Supports | First : | 2 |
Second : | 1.38 |
| MAs | MA(5) : | 2.69 |
MA(20) : | 2.07 |
| MA(100) : | 1.81 |
MA(250) : | 0 | |
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 88.4 |
D(3) : | 91.1 |
| RSI | RSI(14): 81.7 |
|||
| 52-week | High : | 3 | Low : | 0.85 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SLS ] has closed below upper band by 7.0%. Bollinger Bands are 180.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.01 - 3.02 | 3.02 - 3.03 |
| Low: | 2.75 - 2.76 | 2.76 - 2.77 |
| Close: | 2.85 - 2.87 | 2.87 - 2.89 |
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Thu, 25 Dec 2025
How Is The Market Feeling About SELLAS Life Sciences Group Inc? - Benzinga
Thu, 25 Dec 2025
SELLAS Life Sciences (SLS) Is Up 34.6% After Leukemia Data Update Has The Bull Case Changed? - simplywall.st
Thu, 25 Dec 2025
Assessing SELLAS Life Sciences Group (SLS) Valuation After Positive Leukemia Data and Supportive FDA Designations - Yahoo Finance
Wed, 24 Dec 2025
SELLAS Life Sciences Soars: A Game-Changer? - timothysykes.com
Tue, 23 Dec 2025
SELLAS Life Sciences Group, Inc. Stock (SLS) Opinions on Clinical Trial Results - Quiver Quantitative
Tue, 23 Dec 2025
SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025) - ts2.tech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 142 (M) |
| Shares Float | 142 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 23.1 (%) |
| Shares Short | 33,260 (K) |
| Shares Short P.Month | 28,960 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45 % |
| Return on Equity (ttm) | -84.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -10.25 |
| PEG Ratio | 0 |
| Price to Book value | 7.75 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|